Spots Global Cancer Trial Database for relapsed and refractory
Every month we try and update this database with for relapsed and refractory cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | NCT02189343 | Multiple Myelom... | ACY-1215 in com... | 18 Years - | Celgene | |
| Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL | NCT05557903 | Lymphoma, Non-H... Lymphoma, T-Cel... | Recombinant Hum... | 18 Years - 70 Years | Lanzhou Institute of Biological Products Co., Ltd | |
| Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma | NCT03486067 | Multiple Myelom... | CC-93269 | 18 Years - | Celgene | |
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer | NCT03916679 | Ovarian Cancer | anti-MESO CAR-T... | 18 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | NCT03376958 | Relapsed and Re... Diffuse Large B... | Apatinib | 14 Years - 70 Years | Zhengzhou University | |
| MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | NCT03799913 | Ovarian Cancer | anti-MESO CAR-T... Fludarabine Cyclophosphamid... | 18 Years - 70 Years | Zhejiang University | |
| Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions | NCT04790747 | Hematological M... | CAR-T cells | 15 Years - | Zhejiang University | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | NCT02189343 | Multiple Myelom... | ACY-1215 in com... | 18 Years - | Celgene | |
| Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma | NCT03361748 | Multiple Myelom... | bb2121 | 18 Years - | Celgene | |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | NCT03376958 | Relapsed and Re... Diffuse Large B... | Apatinib | 14 Years - 70 Years | Zhengzhou University | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | NCT02282358 | Lymphoma Relapsed and Re... Diffuse Large B... | Mocetinostat | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma | NCT05209620 | Central Nervous... | ICP-022 Pemetrexed | 18 Years - 75 Years | Henan Cancer Hospital | |
| Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03492138 | Multiple Myelom... | ONC201 Ixazomib Dexamethasone | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | NCT02733380 | Diffuse Large B... | Chidamide Vinorelbine Liposomal Doxor... Dexamethasone Thalidomide | 18 Years - 75 Years | Henan Cancer Hospital | |
| Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | NCT02733380 | Diffuse Large B... | Chidamide Vinorelbine Liposomal Doxor... Dexamethasone Thalidomide | 18 Years - 75 Years | Henan Cancer Hospital | |
| Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma | NCT03486067 | Multiple Myelom... | CC-93269 | 18 Years - | Celgene | |
| A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma | NCT04036461 | Multiple Myelom... | CC-99712 BMS-986405 | 18 Years - | Celgene | |
| MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | NCT03799913 | Ovarian Cancer | anti-MESO CAR-T... Fludarabine Cyclophosphamid... | 18 Years - 70 Years | Zhejiang University | |
| Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL | NCT05557903 | Lymphoma, Non-H... Lymphoma, T-Cel... | Recombinant Hum... | 18 Years - 70 Years | Lanzhou Institute of Biological Products Co., Ltd |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
